Issue 108 • July 2021

The hunt for shark squalene alternative

Reducing surgical scarring with drugs

Is a new malaria vaccine on the horizon? 

Time for UK plasma to shine

After 20 years, the UK Government’s ban on the use of UK human blood plasma for the production of plasma-derived therapies has been lifted. So what happens now?

In association with

06/18/2021 15:01:04
  • Home | Time for UK plasma to shine
  • Datwyler
  • In this issue
  • Contents
  • Labcorp
  • UPS Healthcare Company Insight
  • UPS Healthcare
  • Baxter
  • SHL Medical
  • Briefing
  • Industry news
  • The pharma industry briefing
  • Covid-19 executive briefing by GlobalData
  • Mimotopes
  • Mimotopes Company Insight
  • PerkinElmer
  • Comment
  • A new day for Alzheimer’s disease treatment
  • Covid-19 vaccine inequity: the debate over patent waivers intensifies
  • Covid-19 vaccines show efficacy in adolescents
  • International pharmacovigilance for biotechs: forming a strategy
  • Nipro
  • HOF Sonderanlagenbau
  • Myonex
  • In Depth
  • Malaria vaccines through the ages
  • Are competition authorities tightening the rules on pharma M&A?
  • The fishy business of shark squalene
  • Without a trace: can pharma reduce scarring?
  • Blood plasma production: OK for the UK?
  • When the drugs don’t work: can pharma keep up with mental health?
  • The Solubility Company - Company Insight
  • The Solubility company
  • Owen Mumford Company Insight
  • Owen Mumford
  • In Data
  • Deals analysis
  • The pharma industry key list
  • Global markets and indices
  • Macro-economic indicators
  • Macro-economic indicators (page 2)
  • Events
  • Next issue